Predictive Value of Early Changes of Chromogranin A Levels in Patients With Neuroendocrine Tumours Treated With PRRT

Military Institute od Medicine National Research Institute

Status: Completed

Conditions: Early Release of Chromogranin A (CgA)

Treatments: Diagnostic Test: early release of chromogranin A (CgA) in patients with neuroendocrine tumours (NET) treated with peptide receptor radionuclide therapy (PRRT).

Study type: Observational

Funder types: Other

Identifiers

NCT06183047

CgA dynamics

Details and patient eligibility

About

The results of the study suggest that an early change in CgA levels might serve as a prognostic factor in NET patients treated with PRRT.

Enrollment: 38 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• confirmed NET
• peptide receptor radionuclide therapy (PRRT)

Exclusion criteria

• lack of patient consent to a clinical trial

Trial design

38 participants in 1 patient group

patients with neuroendocrine tumours

Description:

We aimed to assess the predictive value of early release of chromogranin A (CgA) in patients with neuroendocrine tumours (NET) treated with peptide receptor radionuclide therapy (PRRT).

Treatment:

Diagnostic Test: early release of chromogranin A (CgA) in patients with neuroendocrine tumours (NET) treated with peptide receptor radionuclide therapy (PRRT).